RT Journal Article
SR Electronic
T1 Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5147
OP 5155
DO 10.21873/anticanres.15332
VO 41
IS 10
A1 TAIKO NAKAZAWA
A1 YUKIYA NARITA
A1 RYOSUKE KUMANISHI
A1 TAKATSUGU OGATA
A1 YUKI MATSUBARA
A1 KAZUKI NOZAWA
A1 KYOKO KATO
A1 KAZUNORI HONDA
A1 TOSHIKI MASUISHI
A1 HIDEAKI BANDO
A1 SHIGENORI KADOWAKI
A1 MASASHI ANDO
A1 KAZUO HARA
A1 MASAHIRO TAJIKA
A1 KEI MURO
YR 2021
UL http://ar.iiarjournals.org/content/41/10/5147.abstract
AB Background/Aim: Metastatic small bowel adenocarcinoma (SBA) is a rare disease with poor prognosis. This study aimed to explore the efficacy and safety of second-line chemotherapy for patients with SBA. Patients and Methods: We retrospectively reviewed the clinical characteristics of 27 metastatic patients with SBA after progression on first-line chemotherapy. The patients were divided into Cohort A, receiving second-line chemotherapy, and Cohort B, receiving best supportive care. Results: Patients in Cohort B had higher age, worse performance status, and higher neutrophil-to-lymphocyte ratio compared with those in Cohort A. Cohort A showed significantly better overall survival (OS) compared with Cohort B (median OS, 15.6 vs. 3.4 months; p=0.002). Objective response rate, disease control rate, and median progression-free survival (PFS) for Cohort A were 7%, 74%, and 5.0 months, respectively. Patients who underwent irinotecan-based chemotherapy showed longer PFS and OS compared with those who underwent taxane-based chemotherapy. No significant adverse events were reported. Conclusion: Second-line chemotherapy for metastatic SBA demonstrated clinical activity with acceptable toxicities.